Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer

被引：0
作者：
I. V. Balalaeva
L. V. Krylova
M. A. Karpova
A. A. Shulga
E. V. Konovalova
E. L. Guryev
S. M. Deyev
机构：
[1] Lobachevsky State University of Nizhny Novgorod,
[2] Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry,undefined
[3] Russian Academy of Sciences,undefined
[4] Sechenov First Moscow State Medical University,undefined
来源：
Doklady Biochemistry and Biophysics | 2022年 / 507卷
关键词：
targeted therapy; recombinant anticancer toxin; DARPin-LoPE; photodynamic therapy; photodithazine; breast cancer; HER2 receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：330 / 333
页数：3
相关论文
共 50 条
  • [41] HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age
    Jesse A. Sussell
    Daniel Sheinson
    Ning Wu
    Bijal Shah-Manek
    Arpamas Seetasith
    Advances in Therapy, 2020, 37 : 1632 - 1645
  • [42] A systematic review of dual targeting in HER2-positive breast cancer
    Kumler, Iben
    Tuxen, Malgorzata K.
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2014, 40 (02) : 259 - 270
  • [43] Optimizing (neo) adjuvant treatment of HER2-positive breast cancer
    Basho, Reva K.
    McArthur, Heather L.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10 : 1 - 13
  • [44] Current and emerging therapies of HER2-positive metastatic breast cancer
    Hernandez-Blanquisett, Abraham
    Touya, Diego
    Strasser-Weippl, Kathrin
    Ruiz, Rossana
    St Louis, Jessica
    Goss, Paul
    BREAST, 2016, 29 : 170 - 177
  • [45] Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment
    Ngamcherdtrakul, Worapol
    Castro, David J.
    Gu, Shenda
    Morry, Jingga
    Reda, Moataz
    Gray, Joe W.
    Yantasee, Wassana
    CANCER TREATMENT REVIEWS, 2016, 45 : 19 - 29
  • [46] HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age
    Sussell, Jesse A.
    Sheinson, Daniel
    Wu, Ning
    Shah-Manek, Bijal
    Seetasith, Arpamas
    ADVANCES IN THERAPY, 2020, 37 (04) : 1632 - 1645
  • [47] Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
    Zhu, Jiujun
    Jiao, Dechuang
    Wang, Chengzheng
    Lu, Zhenduo
    Chen, Xiuchun
    Li, Lianfang
    Sun, Xianfu
    Qin, Li
    Guo, Xuhui
    Zhang, Chongjian
    Qiao, Jianghua
    Yan, Min
    Cui, Shude
    Liu, Zhenzhen
    CANCERS, 2022, 14 (18)
  • [48] HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
    Xu, Luying
    Xie, Yuxin
    Gou, Qiheng
    Cai, Rui
    Bao, Rong
    Huang, Yucheng
    Tang, Ruisi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [49] Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies
    Costa Monteiro, Ines de Paula
    Madureira, Pedro
    de Vasconscelos, Alessandro
    Pozza, Daniel Humberto
    de Mello, Ramon Andrade
    PHARMACOGENOMICS, 2015, 16 (03) : 257 - 271
  • [50] HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy
    Shao, Qiangzu
    Deng, Junge
    Wu, Haoran
    Huang, Zeping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
12345